851 results match your criteria: "Gonadotropin-Releasing Hormone Deficiency in Adults"

Article Synopsis
  • The study aimed to assess the effectiveness and safety of using multiple doses of gonadotropin-releasing hormone agonist (GnRH-a) compared to a single dose during luteal phase support for patients who previously experienced a failed IVF due to luteal phase deficiency.
  • Eighty patients were randomly divided into two groups: one receiving a single dose of GnRH-a after their IVF procedure and the other receiving 14 daily doses of GnRH-a alongside standard support.
  • The multiple-dose group showed significantly better outcomes in terms of overall pregnancy, clinical pregnancy, and live birth rates, alongside higher progesterone levels, indicating that multiple doses of GnRH-a provide improved results without compromising safety.
View Article and Find Full Text PDF

Hypogonadotropic hypogonadism due to variants in : expanding the phenotypic and genotypic spectrum of Martsolf syndrome.

Cold Spring Harb Mol Case Stud

June 2020

Harvard Reproductive Endocrine Sciences Center, Reproductive Endocrine Unit of the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

Article Synopsis
  • Biallelic pathogenic variants in the gene lead to two rare disorders, Warburg Micro syndrome (WARBM) and Martsolf syndrome (MS), which share symptoms like congenital cataracts, intellectual disability, and hypogonadism.
  • A case study of a woman with these symptoms was conducted, where exome sequencing revealed specific variants that confirmed her diagnosis of MS and highlighted the presence of hypogonadotropic hypogonadism.
  • The findings suggest that variants causing complete loss of the gene's function are linked to severe WARBM, while variants with some preserved function are associated with the milder MS phenotype, expanding our understanding of genotype-phenotype relationships in these conditions.
View Article and Find Full Text PDF

Mutations in STUB1 have been identified to cause autosomal recessive spinocerebellar ataxia type 16 (SCAR16), also named as Gordon Holmes syndrome, which is characterized by cerebellar ataxia, cognitive decline, and hypogonadism. Additionally, several heterozygous mutations in STUB1 have recently been described as a cause of autosomal dominant spinocerebellar ataxia type 48. STUB1 encodes C-terminus of HSC70-interacting protein (CHIP), which functions as an E3 ubiquitin ligase and co-chaperone and has been implicated in several neurodegenerative diseases.

View Article and Find Full Text PDF

A Novel SEMA3G Mutation in Two Siblings Affected by Syndromic GnRH Deficiency.

Neuroendocrinology

November 2021

Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy,

Article Synopsis
  • GnRH deficiency causes a rare genetic problem called hypogonadotropic hypogonadism (HH), which affects sexual reproduction and may be linked to other disorders.
  • Researchers wanted to see how a mutation in the SEMA3G gene contributes to HH, especially in cases with other symptoms like intellectual disability.
  • They discovered that SEMA3G is important for the movement of GnRH neurons and that its mutation can change how these neurons behave, which might lead to the problems seen in HH.
View Article and Find Full Text PDF

Importance: Evidence-based treatments from randomized clinical trials for pedophilic disorder are lacking.

Objective: To determine whether a gonadotropin-releasing hormone antagonist reduces dynamic risk factors for committing child sexual abuse.

Design, Setting, And Participants: This academically initiated, double-blind, placebo-controlled, parallel-group, phase 2 randomized clinical trial was conducted at the ANOVA center in Stockholm, Sweden, from March 1, 2016, to April 30, 2019.

View Article and Find Full Text PDF

Background: Two loci (CHD7 and SOX10) underlying Kallmann syndrome (KS) were discovered through clinical and genetic analysis of CHARGE and Waardenburg syndromes, conditions that include congenital anosmia caused by olfactory bulb (CA/OBs) defects and congenital hypogonadotropic hypogonadism (CHH). We hypothesized that other candidate genes for KS could be discovered by analyzing rare syndromes presenting with these signs. Study Design, Size, Duration: We first investigated a family with Gorlin-Goltz syndrome (GGS) in which affected members exhibited clinical signs suggesting KS.

View Article and Find Full Text PDF

Isolated hypogonadotropic hypogonadism (IHH) is a rare disorder characterized by impaired sexual development and infertility, caused by the deficiency of hypothalamic gonadotropin-releasing hormone neurons. IHH is named Kallmann's syndrome (KS) or normosmic IHH (nIHH) when associated with a defective or normal sense of smell. Variants in SEMA3A have been recently identified in patients with KS.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the relationship between GnRH neurons and olfactory structures by examining patients with congenital anosmia and arhinia, who lack the ability to smell and have missing olfactory structures.
  • - Results showed that while male patients exhibited clear signs of GnRH deficiency, some female patients displayed normal reproductive functions, indicating that olfactory systems may not be essential for GnRH neuron migration and activity.
  • - The findings suggest that GnRH neurons can migrate and function independently of olfactory feedback, shedding light on the complexities of human reproductive biology and development.
View Article and Find Full Text PDF

Objective: It has been established that survival and toxicity outcomes in some cancer types could be influenced by haemoglobin (Hb) levels. This study aims to determine if pre-treatment Hb is associated with late toxicity or survival outcomes in prostate cancer.

Methods: Data from one Phase III randomised controlled trial and one single arm translational trial were analysed.

View Article and Find Full Text PDF

Update on methods to enhance growth.

Curr Opin Endocrinol Diabetes Obes

February 2020

Division of Pediatric Endocrinology, University of Washington and Seattle Children's Hospital, Seattle, Washington, USA.

Purpose Of Review: To discuss treatments used to enhance growth in pediatric patients with short stature.

Recent Findings: New data confirm the known efficacy of recombinant human growth hormone (rhGH) in growth hormone deficiency (GHD) and idiopathic short stature. The latest data from the Safety and Appropriateness of Growth hormone Treatment in Europe cohort did not indicate a long-term risk of malignancy in those treated for isolated GHD, but possibly increased risk in those with other diagnoses.

View Article and Find Full Text PDF

A Rare SPRY4 Gene Mutation Is Associated With Anosmia and Adult-Onset Isolated Hypogonadotropic Hypogonadism.

Front Endocrinol (Lausanne)

November 2019

Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Isolated hypogonadotropic hypogonadism (IHH) is a rare, clinically heterogeneous condition, caused by the deficient secretion or action of gonadotropin releasing hormone (GnRH). It can manifest with absent or incomplete sexual maturation, or as infertility at adult-age; in a half of cases, IHH is associated with hypo/anosmia (Kallmann syndrome). Although a growing number of genes are being related to this disease, genetic mutations are currently found only in 40% of IHH patients.

View Article and Find Full Text PDF

Non-functioning pituitary adenoma (NFPA) is one common cause of adult growth hormone deficiency (AGHD). In Japan, a GH-releasing peptide (GHRP)-2 test is used to evaluate GH secretion. Although the cut-off for peak GH during a GHRP-2 test for severe AGHD is ≤9 ng/mL, severe AGHD may further diminish responses (range, nearly no-response to ≤9 ng/mL).

View Article and Find Full Text PDF

Kallmann-de Morsier syndrome (KS) is a genetic disease of the olfactory system characterized by the association of hypogonadotropic hypogonadism also referred to as gonadotropin-releasing hormone (GnRH) deficiency and anosmia or hyposmia (with hypoplasia or aplasia of the olfactory bulbs). Apart from sporadic cases that occur most often, familial Kallmann's syndrome is being described with increasing frequency. Diagnosis is mainly made in adolescents with absence of spontaneous puberty associated with smell disorders with hypoplasia or even aplasia of the bulbs and/or of the olfactory lobes on MRI.

View Article and Find Full Text PDF

We evaluated the effect of combined use of oral oestrogen (E2) and vaginal progesterone (P) to support luteal phase in antagonist intracytoplasmic sperm injection (ICSI) cycles. We analysed data from 176 patients who underwent ICSI cycles with antagonist protocol. P 90 mg vaginal gel once a day and micronised E2 of 4 mg/day, were started from the day of oocyte pick up and continued to the 12th day of embryo transfer.

View Article and Find Full Text PDF

11β-hydroxylase deficiency (11β-OHD) is the second most common form of congenital adrenal hyperplasia (CAH). Males with 11β-OHD CAH are often diagnosed late with a significantly advanced bone age leading to a poor height prognosis due to early closure of epiphysis. Delaying epiphyseal fusion by treatment of aromatase inhibitors (AIs) might be a useful strategy in patients with very advanced bone ages.

View Article and Find Full Text PDF
Article Synopsis
  • Subclinical and clinical thrombosis in bioprosthetic cardiac valves occurs more frequently than previously thought, particularly in patients undergoing hormonal treatments.
  • A notable case study discusses a 40-year-old woman who experienced acute thrombosis of her bioprosthetic mitral valve while undergoing in vitro fertilization, compounded by undiagnosed protein C deficiency.
  • This case highlights the importance of screening for blood clotting risk factors in women with bioprosthetic valves prior to starting gonadotropin stimulation therapy.
View Article and Find Full Text PDF

Congenital hypogonadotropic hypogonadism (CHH) is a condition characterized by absent puberty and infertility due to gonadotropin releasing hormone (GnRH) deficiency, which is often associated with anosmia (Kallmann syndrome, KS). We identified loss-of-function heterozygous mutations in anti-Müllerian hormone () and its receptor, , in 3% of CHH probands using whole-exome sequencing. We showed that during embryonic development, AMH is expressed in migratory GnRH neurons in both mouse and human fetuses and unconvered a novel function of AMH as a pro-motility factor for GnRH neurons.

View Article and Find Full Text PDF

Functional Hypogonadotropic Hypogonadism in Men: Underlying Neuroendocrine Mechanisms and Natural History.

J Clin Endocrinol Metab

August 2019

Harvard Reproductive Endocrine Sciences Center and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

Context: After completion of puberty a subset of men experience functional hypogonadotropic hypogonadism (FHH) secondary to excessive exercise or weight loss. This phenomenon is akin to hypothalamic amenorrhea (HA) in women, yet little is known about FHH in men.

Objective: To investigate the neuroendocrine mechanisms, genetics, and natural history underlying FHH.

View Article and Find Full Text PDF

Delayed Puberty-Phenotypic Diversity, Molecular Genetic Mechanisms, and Recent Discoveries.

Endocr Rev

October 2019

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

This review presents a comprehensive discussion of the clinical condition of delayed puberty, a common presentation to the pediatric endocrinologist, which may present both diagnostic and prognostic challenges. Our understanding of the genetic control of pubertal timing has advanced thanks to active investigation in this field over the last two decades, but it remains in large part a fascinating and mysterious conundrum. The phenotype of delayed puberty is associated with adult health risks and common etiologies, and there is evidence for polygenic control of pubertal timing in the general population, sex-specificity, and epigenetic modulation.

View Article and Find Full Text PDF

GnRH agonist treatment of luteal phase deficiency in HCG-triggered IVF cycles: a matched case-control study.

Reprod Biomed Online

August 2019

Molecular Assisted Reproduction and Genetics, MAR&Gen Clinic, Camino de Ronda 2, Granada 18006, Spain. Electronic address:

Research Question: This study aimed to identify women with IVF failure associated with low serum progesterone levels after embryo transfer in HCG-triggered cycles and to evaluate the effects of gonadotrophin-releasing hormone (GnRH) agonist, administered after embryo transfer, on serum progesterone and pregnancy outcomes in these cases.

Design: Fifty women who failed to achieve an ongoing clinical pregnancy and had abnormally low luteal-phase serum progesterone concentrations in their first IVF attempt were assigned to two matched groups in their subsequent attempt. Twenty-five women were treated with the original protocol plus14 daily injections of GnRH agonist, beginning on the day of oocyte recovery, in their second IVF attempt (group 1).

View Article and Find Full Text PDF

Context: Kisspeptin-neurokinin B (NKB)-dynorphin neurons are critical regulators of the hypothalamic-pituitary-gonadal axis. NKB and dynorphin are hypothesized to influence the frequency of GnRH pulses, whereas kisspeptin is hypothesized to be a generator of the GnRH pulse. How these neuropeptides interact remains unclear.

View Article and Find Full Text PDF

Gordon Holmes syndrome (GDHS) is an adult-onset neurodegenerative disorder characterized by ataxia and hypogonadotropic hypogonadism. GDHS is caused by mutations in the gene encoding the RING-between-RING (RBR)-type ubiquitin ligase RNF216, also known as TRIAD3. The molecular pathology of GDHS is not understood, although RNF216 has been reported to modify several substrates with K48-linked ubiquitin chains, thereby targeting them for proteasomal degradation.

View Article and Find Full Text PDF

Purpose: Congenital hypogonadotropic hypogonadism (CHH) is a rare genetic disorder mostly characterized by gonadotropins release and/or action deficiencies. Both isolated (idiopathic hypogonadotropic hypogonadism) and syndromic (Kallmann) forms are identified depending on the olfactory ability. Clinical and genetic heterogeneities of CHH have been widely explored, thus improving our understanding of the disease's pathophysiology.

View Article and Find Full Text PDF